belantamab mafodotin
gsk
['belantamab']
kastritis et al #eha2023
belantamab in r/r al, phase ii
interim analysis n=25, mayo i-iiia
median cycles 2- responses after 1 dose
48% gr3-4 ocular toxicity
orr 60% in clinical practice ?delay intervals to 6-8 weeks
?future trials pom-belantamab comb 